GPhA to Congress: FDA Proposed Rule on Labeling Risks Widespread Confusion, Undermines Hatch-Waxman

Published Online: Friday, February 28, 2014
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (February 28, 2014) — Today, the Generic Pharmaceutical Association (GPhA) hosted a Congressional briefing highlighting the economic impact and serious dangers to millions of American patients if the Food and Drug Administration’s (FDA) proposed rule on prescription labeling is implemented as drafted.

The briefing for members of Congress and staff featured experts discussing the proposal, which calls for generic manufacturers to unilaterally change product labels, an action currently prohibited by law.

“This proposal directly undermines the ‘sameness’ of generics and their brand counterparts —a fundamental scientific principle that is the very cornerstone of the success of generic medicines in the last thirty years,” said Gordon Johnston, former Deputy Director, FDA Office of Generic Drugs. “The proposed rule paves the way for different versions of safety information for the same products, undermining the important principle of consistency. Disregarding decades of regulatory stability in this way will create unwarranted confusion, raises patient safety concerns and threatens the system that created thousands of affordable options for consumers. ”

Alex Brill, Economist and CEO, Matrix Global Advisors, said, “By allowing label changes without prior FDA review and approval, the proposal will expose generic drug manufacturers to new liability that will drive up costs of generic drugs by at least $4 billion annually and, furthermore, may create confusion in the marketplace for patients, pharmacists and physicians. The resulting cost increase will be borne by both consumers in the form of higher insurance premiums and the government in the form of higher Medicare and Medicaid costs.”

A recent report by Matrix Global Advisors estimates that U.S. health care costs would rise $4 billion annually if the proposed rule is enacted. Medicare and other government programs will incur $1.5 billion in annual new spending, while private insurers and patients will pay $2.5 billion per year.

GPhA opposes the rule in its current form but continues to advocate for a multi-stakeholder collaboration to find a workable solution that does not undermine patient safety or access.

“Generic manufacturers stand ready to engage with the FDA in meaningful dialogue about how the proposed rule can be improved in a way that does not exceed FDA statutory authority or put patients at risk.” said Ralph G. Neas, President and CEO, GPhA.

Resources:
Matrix Global Advisors (MGA) report: FDA’s Proposed Generic Drug Labeling Rule: An Economic Assessment
GPhA Overview and Assessment: Food and Drug Administration’s Proposed Rule Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
Infographic: FDA Proposed Rule Would Cause Dangerous Confusion, Economic Side Effects
Related Articles
Bipartisan legislation introduced in the U.S. House of Representatives today would formally designate pharmacists as healthcare providers under Medicare Part B. Supported by the National Association of Chain Drug Stores, the bill would amend The Social Security Act of 1935 to enable pharmacists to provide to Medicare patients in underserved communities services that pharmacists already are providing for other patients under state law.
Leaders of Senate and House committees with health care jurisdiction should hold oversight hearings to examine the issues that plagued approximately 50,000 beneficiaries who are covered by Aetna Medicare Part D drug plans.
The Generic Pharmaceutical Association announced today that Ralph G. Neas, President and CEO, would be stepping down from his position in the fall of 2015.
Community pharmacists are most concerned about below-cost reimbursement for certain generic drugs as well as exclusionary Medicare drug plans according to a survey conducted by the National Community Pharmacists Association that asked its members to help identify the organization’s 2015 priorities.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$